Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration with O2h

News May 24, 2010

Executives from Heptares Therapeutics and Oxygen Healthcare (O2h) announced an extension of the agreement under which O2h provides multi-FTE -synthetic chemistry services to support discovery programmes at Heptares.

Dr. Miles Congreve, Head of Chemistry said, “We are happy to have signed this new contract with O2h; they have been a solid chemistry partner and have also supported us with some basic ADME, which helps to reduce discovery cycle times.”

Sunil Shah, CEO, O2h “We have had a successful partnership with Heptares Therapeutics and are delighted at this extension for the third year. Heptares has a very innovative technology that we are happy to have supported since inception and believe will lead to new GPCR drugs being discovered.”

Deceased Data: Should Your Online Remains Be Treated Like Physical Remains?

News

In 2018, your death doesn't just leave behind a body. It leaves behind a huge online footprint - your digital remains. A new study asks whether these remains should be treated and respected as a corpse would, and whether museums may provide a blueprint for the preservation process.

Detecting Heart Disease with an AI App

News

The process of assessing and monitoring heart disease, the leading cause of death in the US, is often expensive and time-consuming. A new app that incorporates pulse data to diagnose arterial changes could simplify the whole process.

Fermentation Byproduct Suppresses Seizures in Nerve Agent Poisoning

News

A compound found in trace amounts in alcoholic beverages is more effective at combating seizures in rats exposed to an organophosphate nerve agent than the current recommended treatment.